Friday, July 10, 2026

pharma · Post-bariatric hypoglycaemia · Cushing's disease

Recordati Ireland

Recordati Ireland is a pharma organization headquartered in Cork, IE. Primary therapeutic focus areas include Post-bariatric hypoglycaemia, Cushing's disease, Post-Bariatric Hypoglycaemia. NovaPharmaNews links 4 clinical

Cork, IE HQ
2002 Founded
40 Employees
EMA registrant Type
Company details
Status
Public
HQ
Cork, IE
Founded
2002
Employees
40
Programs
4
Drugs
11
Patents
0
Clinical program

SOM230-RECAG-PK-0605

Phase 1 · other · Post-bariatric hypoglycaemia

SOM230-RECAG-PK-0605 for Post-bariatric hypoglycaemia is a Phase 1 program (other) at Recordati Ireland with 1 ClinicalTrials.gov record(s).

Internal code SOM230-RECAG-PK-0605

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Recordati Ireland
Phase
Phase 1
Modality
other
Indication
Post-bariatric hypoglycaemia
Status
active
Trials
1